# Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

> **NCT06998719** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Bi Nan** · enrollment: 80 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III
- Borderline Resectable Carcinoma

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06998719
- **Lead sponsor:** Bi Nan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2026-05
- **Final completion:** 2027-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06998719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06998719, "Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06998719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*